세계의 유전자 치료 시장 규모, 점유율, 동향, 업계 분석 : 치료 영역별, 벡터 유형별, 어프로치별, 투여 경로별, 지역별 - 예측(2025-2034년)

The gene therapy market size is expected to reach USD 27,250.20 million by 2034, according to a new study by Polaris Market Research. The report "Gene Therapy Market Size, Share, Trends, Industry Analysis Report: By Therapeutic Area (Autoimmune Disorders, Cardiovascular Diseases, Dermatological Disorders, Hematological Disorders, Metabolic Disorders, Muscle-Related Diseases, Oncological Disorders, and Others), Vector Type, Approach, Route of Administration, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Gene therapy involves modifying or replacing unhealthy genes within a patient's cells to treat or prevent disease. Rapid advancements in genetic engineering, along with an increasing understanding of molecular biology, have propelled gene therapy from experimental stages to real-world clinical applications. Researchers and biopharmaceutical companies are investing heavily in developing safe and effective therapies, while regulatory bodies are streamlining approval processes to accelerate gene therapy market expansion.

The demand for gene therapy has surged due to the increasing prevalence of genetic disorders such as Duchenne muscular dystrophy (DMD), sickle cell disease, hemophilia, and cystic fibrosis. Unlike traditional treatment methods that primarily focus on symptom management, gene therapy targets the underlying cause of these diseases at the genetic level. This targeted approach enhances treatment efficacy and offers the potential for long-term or even permanent relief. In recent years, significant breakthroughs in gene-editing technologies, such as CRISPR-Cas9 and zinc finger nucleases (ZFNs), have enabled more precise and efficient gene modifications.

The rising number of regulatory approvals for gene-based treatments is propelling the gene therapy market growth. Government agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have recognized the transformative potential of these therapies. They are expediting the approval process for promising candidates. Therapies such as Zolgensma for spinal muscular atrophy (SMA) and Luxturna for inherited retinal disease have demonstrated remarkable clinical success, paving the way for broader adoption of gene-based therapies or treatments.

Gene Therapy Market Report Highlights

Based on therapeutic area, the oncological disorders segment leads the gene therapy market share in 2024 due to the prevalence of significant physical and psychological impacts of the disease and its treatment.

By vector type, the viral segment leads gene therapy market revenue share due to its effective and efficient delivering genes to the targeted cells for various cancers, monogenic and infectious diseases.

North America leads the gene therapy market due to its robust research infrastructure, advanced healthcare system, significant funding for clinical trials, and a supportive regulatory framework, particularly from the FDA, which allows for rapid development and approval of new gene therapies.

A few global key market players are Abeona Therapeutic, Novartis AG, Spark Therapeutics LLC, Gilead Sciences Inc., Bristol Myers Squibb, Adverum Biotechnologies, Alnylam Pharmaceuticals, American Gene Technologies, Applied Genetic Technologies Corporation, Biogen, and Ultragenyx.

Polaris Market Research has segmented the gene therapy market report on the basis of therapeutic area, vector type, approach, route of administration, and region:

By Type Therapeutic Area Outlook (Revenue, USD Million, 2020-2034)

• Autoimmune Disorders
• Cardiovascular Diseases
• Dermatological Disorders
• Hematological Disorders
• Metabolic Disorders
• Muscle-Related Diseases
• Oncological Disorders
• Others

By Vector Type Outlook (Revenue, USD Million, 2020-2034)

• Viral
• Non-Viral

By Approach Outlook (Revenue, USD Million, 2020-2034)

• Gene Augmentation
• Oncolytic Viral Therapy
• Immunotherapy
• Other Approaches

By Route of Administration Outlook (Revenue, USD Million, 2020-2034)

• Intraarticular
• Intracerebellar
• Intradermal
• Intramuscular
• Intratumoral
• Intravenous
• Intravesical
• Intravitreal
• Subretinal
• Others

By Regional Outlook (Revenue, USD Million, 2020-2034)

• North America
• US
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Netherlands
• Russia
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Malaysia
• South Korea
• Indonesia
• Australia
• Rest of Asia Pacific
• Middle East & Africa
• Saudi Arabia
• UAE
• Israel
• South Africa
• Rest of Middle East & Africa
• Latin America
• Mexico
• Brazil
• Argentina
• Rest of Latin America

Table of Contents

Chapter 1. Introduction

• 1.1 Report Description
  • 1.1.1 Objectives of the Study
  • 1.1.2 Market Scope
  • 1.1.3 Assumptions
• 1.2 Stakeholders

Chapter 2. Executive Summary

Chapter 3. Research Methodology

• 3.1 Overview
  • 3.1.1 Data Mining
• 3.2 Data Sources
  • 3.2.1 Primary Sources
  • 3.2.2 Secondary Sources

Chapter 4. Gene Therapy Market Insights

• 4.1 Gene Therapy - Industry snapshot
• 4.1 Gene Therapy Market Dynamics
  • 4.1.1 Drivers and Opportunities
    • 4.1.1.1 Rising Approval and Investments in Gene Therapy Development
    • 4.1.1.2 Growing Prevalence of Target Diseases
    • 4.1.1.3 Growing Geriatric Population Base
  • 4.1.2 Restraints and Challenges
    • 4.1.2.1 Manufacturing and logistics challenges
    • 4.1.2.2 High Procedure Costs and Presence of Ambiguous Regulatory Framework
    • 4.1.2.3 Lack of Healthcare Infrastructure
• 4.2 Gene Therapy Market - Porter's Five Forces
  • 4.2.1 Bargaining Power of Suppliers (High)
  • 4.2.2 Threats of New Entrants: (Low)
  • 4.2.3 Bargaining Power of Buyers (Moderate)
  • 4.2.4 Threat of Substitute (Low)
  • 4.2.5 Rivalry among existing firms (High)
• 4.3 Gene Therapy Market - PEST Analysis
• 4.4 Covid-19 Impact Analysis & Industry Trends

Chapter 5. Gene Therapy Market Assessment by Therapeutic Area

• 5.1 Introduction
• 5.2 Autoimmune Disorders
• 5.3 Cardiovascular Diseases
• 5.4 Dermatological Disorders
• 5.5 Hematological Disorders
• 5.6 Metabolic Disorders
• 5.7 Muscle-related Diseases
• 5.8 Oncological Disorders
• 5.9 Other Therapeutic Areas

Chapter 6. Gene Therapy Market Assessment by Vector Type

• 6.1 Introduction
• 6.2 Viral
  • 6.2.1 Retroviral vectors
    • 6.2.1.1 Gamma-retroviral vectors
    • 6.2.1.2 Lentiviral vectors
  • 6.2.2 Adeno-associated virus vectors
  • 6.2.3 Other viral vectors
• 6.3 Non-Viral
  • 6.3.1 Oligonucleotides
  • 6.3.2 Other non-viral vectors

Chapter 7. Gene Therapy Market Assessment by Approach

• 7.1 Introduction
• 7.2 Gene Augmentation
• 7.1 Oncolytic Viral Therapy
• 7.2 Immunotherapy
• 7.3 Other Approaches

Chapter 8. Gene Therapy Market Assessment by Route of Administration

• 8.1 Introduction
• 8.2 Intraarticular
• 8.3 Intracerebellar
• 8.4 Intradermal
• 8.5 Intramuscular
• 8.6 Intratumoral
• 8.7 Intravenous
• 8.8 Intravesical
• 8.9 Intravitreal
• 8.10 Subretinal
• 8.11 Others

Chapter 9. Gene Therapy Market Assessment by Region

• 9.1 Introduction
• 9.2 Gene Therapy Market - North America
  • 9.2.1 Gene Therapy Market - U.S.
  • 9.2.2 Gene Therapy Market - Canada
• 9.3 Gene Therapy Market - Europe
  • 9.3.1 Gene Therapy Market - Germany
  • 9.3.2 Gene Therapy Market - UK
  • 9.3.3 Gene Therapy Market - France
  • 9.3.4 Gene Therapy Market - Italy
  • 9.3.5 Gene Therapy Market - Spain
  • 9.3.6 Gene Therapy Market - Netherlands
  • 9.3.7 Gene Therapy Market - Austria
• 9.4 Gene Therapy Market - Asia Pacific
  • 9.4.1 Gene Therapy Market - China
  • 9.4.2 Gene Therapy Market - India
  • 9.4.3 Gene Therapy Market - Japan
  • 9.4.4 Gene Therapy Market - South Korea
• 9.5 Gene Therapy Market - Latin America
  • 9.5.1 Gene Therapy Market - Brazil
  • 9.5.2 Gene Therapy Market - Mexico
• 9.6 Gene Therapy Market - Middle East & Africa
  • 9.6.1 Gene Therapy Market - Saudi Arabia
  • 9.6.2 Gene Therapy Market - UAE

Chapter 10. Competitive Landscape

• 10.1 Key Market Players: Categorization
• 10.2 Strategy Framework
• 10.3 Vendor Landscape
• 10.4 Strategies Categorization
  • 10.4.1 Partnerships/Collaborations/Agreements
  • 10.4.2 Expansions/Mergers/Acquisitions
  • 10.4.3 Product Development/New Launch

Chapter 11. Company Profiles

• 11.1 Sangamo Biosciences
  • 11.1.1 Business Overview
  • 11.1.2 Financial Snapshot
  • 11.1.3 Products and Services
  • 11.1.4 Recent Developments
• 11.2 Voyager Therapeutics
  • 11.2.1 Business Overview
  • 11.2.2 Financial Snapshot
  • 11.2.3 Products and Services
  • 11.2.4 Recent Developments
• 11.3 Ultragenyx
  • 11.3.1 Business Overview
  • 11.3.2 Financial Snapshot
  • 11.3.3 Products and Services
  • 11.3.4 Recent Developments
• 11.4 GlaxoSmithKline
  • 11.4.1 Business Overview
  • 11.4.2 Financial Snapshot
  • 11.4.3 Products and Services
  • 11.4.4 Recent Developments
• 11.5 Gilead Sciences Inc
  • 11.5.1 Business Overview
  • 11.5.2 Financial Snapshot
  • 11.5.3 Products and Services
  • 11.5.4 Recent Developments
• 11.6 Bristol Myers Squibb
  • 11.6.1 Business Overview
  • 11.6.2 Financial Snapshot
  • 11.6.3 Products and Services
  • 11.6.4 Recent Developments
• 11.7 Novartis AG
  • 11.7.1 Business Overview
  • 11.7.2 Financial Snapshot
  • 11.7.3 Products and Services
  • 11.7.4 Recent Developments
• 11.8 Spark Therapeutics LLC
  • 11.8.1 Business Overview
  • 11.8.2 Products and Services
  • 11.8.3 Recent Developments
• 11.9 Bluebird Bio
  • 11.9.1 Business Overview
  • 11.9.2 Recent Developments
  • 11.9.3 Products and Services
  • 11.9.4 Recent Developments